ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



Ò½ÏßÒ©ÎÅ1. ¿ËÈÕ£¬£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬£¬°²Áì¿ÆÉúÎïÉ걨µÄ1ÀàÐÂÒ©×¢ÉäÓÃALK202»ñÅúÁÙ´²£¬£¬£¬£¬£¬£¬ÄâÓÃÓÚ¼ÈÍù±ê×¼ÖÎÁÆÊ§°Ü»òÎÞ±ê×¼ÖÎÁÆ£¨°üÀ¨ÎÞ·¨½ÓÊܱê×¼ÖÎÁÆ£©µÄ³ÉÈ˾ֲ¿ÍíÆÚ»ò×ªÒÆÐÔʵÌåÁö¡£¡£¡£Æ¾Ö¤°²Áì¿ÆÉúÎï¹ÙÍø¹ÜÏß×ÊÁÏ¿ÉÖª£¬£¬£¬£¬£¬£¬ÕâÊÇÒ»¿î°ÐÏòEGFR/CMETµÄË«ÌØÒìÐÔ¿¹ÌåżÁªÒ©ÎADC£©¡£¡£¡£
2. ¿ËÈÕ£¬£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬£¬°¬²©ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾É걨µÄ¶³¸ÉºôÎüµÀºÏ°û²¡¶¾mRNAÒßÃçµÄINDÉêÇëÒÑ»ñµÃÁÙ´²Ä¬Ê¾ÔÊÐí¡£¡£¡£
3. ¿ËÈÕ£¬£¬£¬£¬£¬£¬ÈÙ²ÓÉúÎïÒ½Ò©¼¼Êõ£¨ÉϺ££©ÓÐÏÞ¹«Ë¾×ÔÖ÷Ñз¢µÄÈËÈéÍ·Áö²¡¶¾£¨HPV£©ÖÎÁÆÐÔmRNAÒßÃçÒÑ»ñµÃÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨FDA£©µÄÁÙ´²ÊÔÑéÔÊÐí¡£¡£¡£
4. 3ÔÂ4ÈÕ£¬£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬£¬°Ù¼ÃÉñÖÝÉ걨µÄ1ÀàÐÂÒ©×¢ÉäÓÃBGB-C354»ñµÃÒ»ÏîеÄÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬£¬£¬ÄâÁªºÏÌæÀ×ÀûÖéµ¥¿¹ÖÎÁÆÍíÆÚʵÌåÁö»¼Õß¡£¡£¡£¹ûÈ»×ÊÁÏÏÔʾ£¬£¬£¬£¬£¬£¬BGB-C354ÊÇÒ»¿î°ÐÏòB7H3µÄ¿¹ÌåżÁªÒ©ÎADC£©
1. ¿ËÈÕ£¬£¬£¬£¬£¬£¬ËÄ´¨ÑáÑõÉúÎï¿Æ¼¼ÓÐÏÞÔðÈι«Ë¾ÓëÍòÔó¹É·ÝÈ«×Ê×Ó¹«Ë¾ÄÚÃɹÅË«ÆæÒ©Òµ¹É·ÝÓÐÏÞ¹«Ë¾ÕýʽǩÊð¡¶ËÄ´¨ÑáÑõÉúÎï¿Æ¼¼ÓÐÏÞÔðÈι«Ë¾ÓëÄÚÃɹÅË«ÆæÒ©Òµ¹É·ÝÓÐÏÞ¹«Ë¾Ö®ÔÊÐíÐÒé¡·£¬£¬£¬£¬£¬£¬¾ÍÁÙ´²½×¶Î΢Éú̬»îÌåÉúÎïÁ¢ÒìÒ©£¨ÒõµÀÓÃËÄÁªÈé¸Ë¾ú»î¾ú½ºÄÒ£¬£¬£¬£¬£¬£¬ÏîÄ¿´úºÅ¡°KAL-001¡±£©ÔÚ´óÖлªÇø£¨°üÀ¨Öйú´ó½¡¢Ïã¸Û¡¢°ÄÃż°Ì¨Í壩µÄ¹¤Òµ»¯¼°ÉÌÒµ»¯¶ÀÍÌÈ¨Òæ¸æ¿¢ÏàÖú¡£¡£¡£
1. 2ÔÂ25ÈÕ£¬£¬£¬£¬£¬£¬¸´µ©´óѧÄÔ¿ÆÑ§Ñо¿ÔºÑîÕñ¸Ù¿ÎÌâ×飬£¬£¬£¬£¬£¬ÓÚÆÚ¿¯PNAS½ÒÏþÌâΪ¡¶NOTCH¡¢ERKºÍSHHÐźÅͨ·¿ØÖÆ´óÄÔÆ¤ÖʽºÖÊϸ°ûºÍÐáÇòÖÐÐÄÉñ¾ÔªµÄÔËÆø¾öÒé¡·(NOTCH, ERK, and SHH signaling respectively control the fate determination of cortical glia and olfactory bulb interneurons)µÄÂÛÎÄ¡£¡£¡£¸ÃÑо¿ÎªÖÜÈ«Ã÷È·´óÄÔÄÚÖÖÖÖϸ°û·¢ÓýµÄ»ù±¾¼ÍÂÉÔöÌíÁËеÄ֪ʶ¡£¡£¡£Õâ¶ÔÄÔ½ºÖÊÁöµÄ²î±ðÑÇÐ͵ÄÕïÁÆÒ²¿ÉÄÜÌṩÁËÒ»¸öеÄÊӽǡ£¡£¡£
[1]Therapeutic circRNA aptamer alleviates PKR-associated osteoarthritis. Science Bulletin (2025). https://doi.org/10.1016/j.scib.2025.02.027
Ïà¹ØÐÂÎÅ